GlaxoSmithKline is close to ending a six-decade drought in relapse-preventing therapies for Plasmodium vivax—one of the most common forms of malaria.

Pliant Therapeutics has raised a healthy $62 million series B to help fund its proof of concept tests across a range of scarring diseases.

Urovant filed to raise $150 million in its IPO, which will push the company's lead asset through the clinic in a pair of indications.

New HIV treatments could target a molecule called IP6 to render the virus vulnerable to the immune system.

Octave Biosciences picked up a pair of industry veterans for its board of directors, as well as $14 million to advance its care management technology.

Modus Therapeutics raised over 140 million Swedish krona, or about $15.7 million, to advance clinical studies of sevuparin in sickle cell disease.

Celgene has raised the top dose and expanded its trial of Bluebird Bio myeloma CAR-T bb2121 but still thinks it’s on course for approval in 2020.

The CFO/COO departed months after he was implicated in a scandal that engulfed his former employer.

Gilead's clinical director joins Nimbus to lead discovery; Immunocore’s CMO jumps to Tmunity; Kite taps Eisai vet to lead CAR-T sales.

The revised filing pools all the phase 3 data in a bid to show the sclerostin-targeting antibody has a positive risk-benefit profile.